Several days following the Federal Drug Administration’s approval of a new cancer drug, Erik Nelson (ACPP) was still processing the news.

“It hasn’t sunk in yet that this is actually happening,” he said from his breast cancer research lab in Burrill Hall. “This is why I get up every morning: to hopefully impact a patient's life.”